Cover Image
市場調查報告書

作為鈣離子阻斷劑(用作偏頭痛治療藥):市場預測與分析

Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 301152
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
作為鈣離子阻斷劑(用作偏頭痛治療藥):市場預測與分析 Calcium Channel Antagonists (Migraine) - Forecast and Market Analysis to 2023
出版日期: 2014年03月31日 內容資訊: 英文 42 Pages
簡介

鈣離子阻斷劑當初由於具有擴張腦血管結構上血管的效果,而成為眾所關注的偏頭痛治療法(Montastruc and Senard, 1992)。但其效果大半是藉由介入緩慢的膜電位依賴性通道,以阻斷跨膜內流的鈣離子通過。鈣離子通道依細胞內部、外部不同位置而分為不同種類──電壓門控性鈣離子通道(依電壓高低開啟關閉)、配體門控性鈣離子通道(依化學傳達物質開啟關閉)。

本報告提供偏頭痛治療藥──鈣離子阻斷劑的全球市場相關分析,提供偏頭痛概要和治療方法,競爭的企業·藥品概要,市場競爭概況,藥物的商品資訊(特色·功效·安全性等),全球主要國家的市場販售額預測(今後10年份)等調查,並將結果概述為以下內容。

第1章 目錄

第2章 簡介

  • 本報告概要
  • 相關調查
  • 近日出版的相關調查

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
    • 預測
  • 症狀
    • 前驅症狀階段
    • 前兆階段
    • 疼痛的階段
    • 後發症狀的階段

第4章 疾病管理

  • 治療方法概要
    • 急性偏頭痛的治療
    • 偏頭痛的預防療法

第5章 競爭企業的評估

  • 概要
  • 競爭企業的策略性評估

第6章 偏頭痛治療藥的鈣離子阻斷劑

  • 概要
  • 功效
  • 安全性
  • SWOT分析
  • 未來預測

第7章 附錄

圖表一覽

目錄
Product Code: GDHC377DFR

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Calcium channel antagonists initially evoked interest in the treatment of migraine due to their vasodilator effects on the cerebral vasculature (Montastruc and Senard, 1992). However, their effects are most likely due to blocking the transmembrane influx of calcium across cell membranes through slow, voltage-dependent channels. Calcium channels are located extracellularly or intracellularly and consist of different subtypes: those that are voltage-gated (opened by depolarization) and ligand-gated (opened by chemical messengers).

Scope

  • Overview of Migraine, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Calcium channel antagonists including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Calcium channel antagonists for the top two countries from 2012 to 2023.
  • Sales information covered for the Italy and Japan.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Migraine
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Calcium channel antagonists performance
  • Obtain sales forecast for Calcium channel antagonists from 2012-2023 in the top two countries (Italy and Japan)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
  • 3.2. Symptoms
    • 3.2.1. Premonitory Phase
    • 3.2.2. Aura Phase
    • 3.2.3. Headache Phase
    • 3.2.4. Postdrome Phase

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Acute Migraine Treatment
    • 4.1.2. Preventive Migraine Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Calcium Channel Antagonists

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Migraine Patients
    • 7.4.2. Percent Drug-treated Patients
    • 7.4.3. General Pricing Assumptions
    • 7.4.4. Individual Drug Assumptions
    • 7.4.5. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. Survey of Prescribing Physicians
  • 7.7. About the Authors
    • 7.7.1. Author
    • 7.7.2. Reviewer
    • 7.7.3. Global Head of Healthcare
  • 7.8. About GlobalData
  • 7.9. Disclaimer

List of Tables

  • Table 1: Classification of Migraine Subtypes
  • Table 2: Diagnostic Criteria for Migraine with Aura
  • Table 3: Diagnostic Criteria for Migraine without Aura
  • Table 4: Treatment Guidelines for Migraine
  • Table 5: Most Prescribed Drugs for Migraine by Class in the Major Markets, 2013
  • Table 6: Product Profile-Calcium Channel Antagonists
  • Table 7: Calcium Channel Antagonists SWOT Analysis, 2013
  • Table 8: Global Sales Forecasts ($m) for Calcium Channel Antagonists, 2012-2023
  • Table 9: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Migraine Treatment Algorithm in the 7MM
Back to Top